There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 2 | 4 | 1167.3 |
| 2 | 14 | 1167.2 |
| 2 | 37 | 1167.1 |
| 2 | 109 | 1167 |
| 2 | 35 | 1166.9 |
| Ask | Qty | Orders |
|---|---|---|
| 1168.3 | 2 | 43 |
| 1168.4 | 5 | 44 |
| 1168.5 | 5 | 79 |
| 1168.6 | 2 | 3 |
| 1168.7 | 3 | 45 |
Annual Revenue,rose 29.47%, in the last year to ₹2,241.62 Cr. Its sector's average revenue growth for the last fiscal year was 12.11%.Annual Net Profit,rose 105.08% in the last year to ₹348.91 Cr. Its sector's average net profit growth for the last fiscal year was 2.24%.Quarterly Revenue,rose 3.91% YoY to ₹617.66 Cr. Its sector's average revenue growth YoY for the quarter was 12.58%.Sai Life Sciences Limited is a fully integrated Contract Research, Development and Manufacturing Organisation (CRDMO) specialising in small-molecule new chemical entities. Established in 1999, the company began with medicinal chemistry services before evolving into an end-to-end partner for pharmaceutical and biotechnology companies, supporting them across discovery, development, and commercial manufacturing.
Headquartered in Hyderabad, Sai Life Sciences operates large R&D and manufacturing sites in India, with additional laboratories near key innovation hubs in the US (Greater Boston) and the UK (Manchester), ensuring proximity to clients and offering economical scale-up options.
The company caters to a global innovator client base, including 18 of the world’s top 25 pharmaceutical companies by revenue (CY2024). It serves regulated markets such as the US, Europe, and Japan. By maintaining operations across India, the US, and the UK, Sai Life Sciences ensures smooth technology transfers and scale-ups, while manufacturing activities remain India-based.
The company has three subsidiaries (not named) and achieved several milestones, including successful USFDA and PMDA audits at its facilities, expansion of the Bidar site, and investments in research centres in Boston and Manchester. Sai Life Sciences made its public debut with a stock exchange listing on December 18, 2024, when its equity shares commenced trading on the NSE and BSE.
CRDMO services – 100% of turnover, covering discovery, development, and commercial manufacturing for small molecules.
Sai Life Sciences is an integrated CRDMO offering discovery, development, and commercial manufacturing services for small molecules. It partners with global pharmaceutical and biotechnology innovators to accelerate lab-to-market programs.
The company was listed on NSE and BSE on December 18, 2024. The IPO was oversubscribed 10.27 times and resulted in a premium listing on both exchanges
Approximately 97% of revenue is generated from North America, Europe, Japan, and the UK, supported by laboratory presence in the US and UK and manufacturing in India.
